

sub
C1
A3
cont.

26. A process comprising the steps of:
- (a) performing the assay according to claim 24;
 - (b) identifying one or more agents that do affect PDE1B2 expression; and
 - (c) preparing a quantity of those one or more identified agents.


27. A method of affecting in vivo PDE1B2 expression with an agent, wherein the agent is capable of affecting PDE1B2 expression in an in vitro assay method; wherein the in vitro assay method is the assay method defined in claim 24, said method comprising administering said agent to a subject.

Remarks:

It is believed that the above-indicated claim amendments place the present case in condition for allowance. Therefore, a Notice of Allowance is courteously solicited.

Date: 9/15/00

Respectfully submitted,


Gregory P. Raymer
Attorney for Applicants
Reg. No. 36,647

Pfizer Inc
Patent Department
Eastern Point Road
Groton, CT 06340
(860) 715-5746

Express Mail No. EL709318682US

BEST AVAILABLE COPY

005150-2459960